In this role, Dr. Hansson will be responsible for leading clinical research and development activities around NeuroVive’s therapeutic candidates and discovery platforms, reporting to Jan Nilsson, interim Chief Executive Officer and working closely with CSO Eskil Elmér and the core team of scientists at NeuroVive.
An immediate priority for Dr. Hansson will be to advance NeuroVive’s leadership position in mitochondrial medicine with a focus on ensuring successful clinical research and development of NeuroVive’s lead candidates, NeuroSTAT® in traumatic brain injury and CicloMulsion® in acute kidney injury (AKI). Dr. Hansson will also be involved in progressing products from the discovery platforms into the clinical stage of development.
“Magnus has extensive research experience in the field of disease mechanisms in acute cardiovascular and neurological disorders and in the past has provided valuable input to the NeuroVive development program,” said Jan Nilsson. “Accelerating research and development is a core business priority for NeuroVive and we are delivering on this by putting in place a dedicated resource within the research and development team. Magnus’ expertise in translational research within mitochondrial medicine will be instrumental in progressing our research and development work in which we aim to bring innovative investigational therapies to market.”
Dr. Hansson is a long-standing member of NeuroVive’s scientific team, serving as the primary clinical scientist for the CicloMulsion® studies. Parallel to his previous part-time position at NeuroVive, Dr. Hansson has been serving as a consultant physician and associate professor in medical imaging and physiology at Skåne University Hospital, Sweden. Hansson received his medical degree and PhD in Experimental brain research from Lund University, Sweden and has authored more than 30 scientific publications and 10 patent applications.
About NeuroVive
NeuroVive Pharmaceutical AB (publ) is a leading mitochondrial medicine company committed to the discovery and development of highly targeted candidates that preserve mitochondrial integrity and function in areas of therapeutic need. NeuroVive’s business approach is driven by value-adding partnerships with leading mitochondrial research institutions and commercial partners across the globe.
NeuroVive’s portfolio consists of two clinical projects in acute kidney injury (AKI) and traumatic brain injury (TBI) and two drug discovery platforms. The NeuroSTAT® product is currently being evaluated in a Phase II study in traumatic brain injury. CicloMulsion® is being evaluated in an ongoing Phase II study, CiPRICS, in acute kidney injury during heart surgery. NeuroVive’s shares are listed on NASDAQ OMX, Stockholm, Sweden.
Disclaimer
This release may contain forward-looking statements that can be identified by words such as “recommends,” “indicating,” “risk,” “recommended,” “believe,” “could,” “commitment,” “will,” “implications,” “supports,” “thought,” “designed,” “growing,” “continues,” or similar terms, or by express or implied discussions regarding potential marketing approvals for CicloMulsion®, or regarding potential future revenues from CicloMulsion®. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that CicloMulsion® will be submitted or approved for sale in any market, or at any particular time. Nor can there be any guarantee that CicloMulsion® will be commercially successful in the future. In particular, management’s expectations regarding CicloMulsion® could be affected by, among other things, the uncertainties inherent in research and development, including unexpected clinical trial results and additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company’s ability to obtain or maintain proprietary intellectual property protection; general economic and industry conditions; global trends toward health care cost containment, including ongoing pricing pressures; unexpected manufacturing issues, and other risks and factors.
For investor relations and media questions in Sweden, please contact:
Johannes Nebel, Laika Consulting, Tel: +46 (0)735 81 71 68 or ir@neurovive.se
For media questions outside Sweden, please contact:
Gemma White, inVentiv Health, Tel: +44 (0)77 13 88 9992 or gemma.white@inventivhealth.com
It is also possible to arrange an interview with NeuroVive’s CEO Jan Nilsson at the above contacts.
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
info@neurovive.se, www.neurovive.com
NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on the 23 October 2015, at 08.30 CET.